Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer
Authors' conclusion
Active surveillance is a viable option for asymptomatic patients with progressive RAI-R DTC. However, early intervention with MKI therapy may be more suitable for others. Further research is needed to identify patients who are optimal for active surveillance.
Study context
- Population
- Asymptomatic patients with progressive RAI-refractory differentiated thyroid cancer (DTC) (≥1 lesion ≥1 cm in diameter), US and non-US populations
- Participants
- 647 patients
- Exposure
- MKI therapy vs active surveillance at study entry
- Cohort 1n = 169
- Cohort 2n = 478reference
- Outcome
- Time to symptomatic progression (TTSP) from study entry
Methodological detailsopen-label, physician-chosen treatment
- Open-label
- Physician-chosen treatment
Main finding
As reported in the abstract
36-month TTSP rate from study entry, Cohort 2 · 36 months
Cohort 2, US population
65.6%
Cohort 2, non-US population
66.5%
Observational data: associations, not effects.
Further findings
Surveillance rate by population
- US population
- 92.6%
- Non-US population
- 66.9%
36-month time to symptomatic progression (TTSP) rate, Cohort 2 patients treated later with MKI
- US population
- 30.8%
- Non-US population
- 55.8%
Initial American Thyroid Association (ATA) risk in patients qualifying for MKI treatment
- Half of US and non-US patients had initial ATA low-to-intermediate-risk disease
Original publication
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer. Eur Thyroid J. Published 24 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →